<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04182672</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-18-0672</org_study_id>
    <nct_id>NCT04182672</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric Bursitis</brief_title>
  <official_title>Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric Bursitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Flexion Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of Zilretta (FX006) in&#xD;
      bursal injections and to assess the patient's impression to change in treatments, to their&#xD;
      chronic pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain from baseline as assessed by the Numeric Pain Rating Scale (NPRS) score</measure>
    <time_frame>Baseline,week 12</time_frame>
    <description>Numeric Pain Rating Scale total score ranges from 0 (no pain) to 10 (most intense pain imaginable).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in patient's impression to change in treatment,to their chronic pain as measured by the Patient Global Impression of Change (PGIC) measure</measure>
    <time_frame>Baseline,week 12</time_frame>
    <description>The PGIC is a 7 point scale ranging from very much improved (1) to very much worsened (7)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Trochanteric Bursitis</condition>
  <arm_group>
    <arm_group_label>Zilretta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zilretta</intervention_name>
    <description>Subjects will be injected with the 5ml of FX006. This injection may be followed with up to 3ml of ropivacaine (depending on the capacity of the bursa), under ultrasound guidance.</description>
    <arm_group_label>Zilretta</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written consent to participate in the study&#xD;
&#xD;
          -  Symptoms consistent with greater trochanteric bursitis for greater than or equal to 3&#xD;
             months prior to screening (patient reported is acceptable)&#xD;
&#xD;
          -  Pain in hip for greater than 15 days over the last month (as reported by the patient).&#xD;
&#xD;
          -  Hip bursitis as determined by clinical examination and clinical features. Where&#xD;
             Magnetic Resonance Imaging (MRI) data is available, it will be used to confirm the&#xD;
             bursitis diagnosis. Also, pain relief in subjects that have been treated with bursal&#xD;
             injections containing an anesthetic (such as ropivacaine) is in itself indicative of&#xD;
             bursitis.&#xD;
&#xD;
          -  Body mass index (BMI) less than or equal to 40 kg/m2&#xD;
&#xD;
          -  Ambulatory and in good general health&#xD;
&#xD;
          -  Willing and able to comply with the study procedures and visit schedules and able to&#xD;
             follow verbal and written instructions.&#xD;
&#xD;
          -  Willing to abstain from use of protocol-restricted medications during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hip Arthroplasty&#xD;
&#xD;
          -  Hip osteoarthritis, iliopsoas bursitis, reactive arthritis,rheumatoid arthritis,&#xD;
             psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory&#xD;
             bowel disease&#xD;
&#xD;
          -  History of local infection around the bursa.&#xD;
&#xD;
          -  Lack of pain relief with the intrabursal treatments containing an anesthetic&#xD;
&#xD;
          -  Intra-bursal treatment of any bursa with any of the following agents within three (3)&#xD;
             months of screening: any corticosteroid preparation (investigational or marketed,&#xD;
             including FX006); and/or six (6) months for any biologic agent (e.g., platelet rich&#xD;
             plasma (PRP) injection, stem cells, prolotherapy, amniotic fluid injection;&#xD;
             investigational or marketed).&#xD;
&#xD;
          -  Parenteral or oral corticosteroids (investigational or marketed) within 3 months of&#xD;
             Screening&#xD;
&#xD;
          -  Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2&#xD;
             weeks of screening.&#xD;
&#xD;
          -  Females who are pregnant or nursing or plan to become pregnant during the study; women&#xD;
             who plan to conceive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pritish Bawa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pritish Bawa, MD</last_name>
    <phone>713-500-7706</phone>
    <email>Pritish.bawa@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Donna Hall</last_name>
    <phone>713-704-1787</phone>
    <email>Donna.J.Hall@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pritish Bawa, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Donna Hall</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>November 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2019</study_first_posted>
  <last_update_submitted>October 24, 2021</last_update_submitted>
  <last_update_submitted_qc>October 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Pritish Bawa</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Hip bursitis</keyword>
  <keyword>hip pain</keyword>
  <keyword>Zilretta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bursitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

